The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

A Promising Pocket Pharma Like This Could Pluck Perky Pickings. But You Need Nerve.

By Malcolm Stacey | Wednesday 11 October 2017

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Hello, Share Choosers. As we've often said on this glittering website, investing in small drugs companies is fraught with peril. Cures and remedies take so long to develop, and then you have to steer them through a punishing licence minefield. I’m a great believer, though, in this kind of punt as the world becomes older and less healthy. And investment in the right pharma could reap big rewards for shareholders, but mainly the sick among us. Today’s suggestion seems a more promising pocket pharma than most.

ImmuPharma (IMM) is listed on AIM, where so any drugs explorers are represented. Even though it takes an awful lot of money to develop a world-beating cure.

As far as I can see, ImmuPharma is an interesting hope for conditions caused by over-enthusiastic immune systems. One of its most important drugs under development now is Lupuzor. As you might imagine from the name, it is meant for the treatment of Lupus. As well as other auto-immune diseases.

And this is a big potential market. For instance, it’s been estimated that 50 million Americans have some form of auto-immune disease.

The path, as with all similar companies, is not smooth.The company announced a £3 million loss for the first half of the year. But their studies in Lupuzor are encouraging.

More than a quarter of the study patients have now completed the sixth-month study. What’s needed now is permission from the European Medicines Agency and the US Food and Drug Administration. The plan then is to have Lupozior ready for next Spring.

OK, there’s many a slip twixt cup and lip. But this company has money in the coffers and is expecting success. Nor is Lupuzor the only drug in its portfolio 

If you are prepared for setbacks and want to improve the health of the world, as well as making big money, then this kind of company, with some promising ideas in the pipeline, should be worth a try.

And now please join me in the Punter’s Return.

















Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on IMM


Comments are turned off for this article.

Site by Everywhen